Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man
about
Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivoryThe effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patientsRegulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagusPharmGKB summary: very important pharmacogene information for UGT1A1Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingThe effects of microRNA on the absorption, distribution, metabolism and excretion of drugsMultiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Structure and Protein-Protein Interactions of Human UDP-GlucuronosyltransferasesLineage-Specific Changes in Biomarkers in Great Apes and HumansGenetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese populationThe last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.Getting to 90-90-90 in paediatric HIV: What is needed?Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus.Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymesThe inverse starving test is not a suitable provocation test for Gilbert's syndromeCombined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome.Molecular analysis of patients of Sardinian descent with Crigler-Najjar syndrome type IUGT1A1 sequence variants and bilirubin levels in early postnatal life: a quantitative approachBilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposonImportance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemiaSplice-site mutations: a novel genetic mechanism of Crigler-Najjar syndrome type 1.Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotideDiscrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice.Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia.Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal HyperbilirubinemiaRole of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia.Disruption of the c/ebp alpha gene in adult mouse liver.Three-dimensional polyacrylamide gel-based DNA microarray method effectively identifies UDP-glucuronosyltransferase 1A1 gene polymorphisms for the correct diagnosis of Gilbert's syndromePredictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.Excretion of biliary compounds during intrauterine life.Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors.Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer.
P2860
Q21091054-21CE406D-1F18-42BC-ACAC-2D3B57B3725EQ21559550-4312359D-1A24-4B01-AD0F-159557586EF8Q24531398-66EE0F93-846F-43D3-9E69-6F0D978B2B92Q24562836-08062663-DB15-4AE2-937C-AFF66D09D923Q26784507-69BB7606-03D6-485B-B4C8-1A7258265A5BQ26822987-13A5DD52-2BF9-4CDC-80BA-DDEA72BC21F1Q27334876-1F84FDC9-22DE-4F10-BBBB-FE899FCED978Q28071266-4148E7AD-2DA2-4735-94D1-8A45AE3DFEF8Q28547060-531D6C22-BE06-4E2C-8D84-4BB1901FC8BDQ28730582-39B73045-7417-4789-BB72-AD248A7A26A0Q30382184-CBD337E2-CFC6-4858-A235-A17011A89136Q30385352-A6640C6F-2F6C-4206-9AC3-01A9614E03E2Q30493784-0FABD9E5-1C77-4C6B-BC95-4AEEAA580237Q33283468-A2D127A8-ACDC-4D58-8F73-CD7582F6485BQ33360903-C00CFD46-53F7-45A6-AE33-BC07B9794AEBQ33597058-9D327591-C0AC-42DB-AB54-3AAF62D3EE3DQ33678402-B6033F32-04F9-434F-8D2E-84EA4E7E49FCQ33879801-9085728F-B228-411A-B110-5B6C01676027Q34011206-CD65CB95-E30A-42FE-B728-EB7EE581EDA0Q34207748-77CF55A9-3CF2-4A2C-8A97-2C6A29F69D62Q34240331-7958317E-E2DB-4FEA-BBC9-E8FFFAB5532DQ34364347-61DD01BA-CDA6-4949-B58B-0B26D64FF7C5Q34384716-D1CE02CA-7483-4A38-853D-E2E25D4A81F6Q35620922-F2E8906B-661F-4AB9-907C-7C96AB358FB7Q35824577-7B6C7DAE-B972-4256-83CA-9BCF25474F9FQ36060527-C6CD1159-759C-4D33-8FF0-A1843A929327Q36191283-E2CE51BE-00D5-4336-99C9-D4BF4A560D6FQ36432411-0334DCFE-67C1-494D-8A91-634162ACA704Q36450835-E5110233-EB9A-44BA-AE70-CD5997D924EDQ36573179-E28EBB27-0D70-401D-B774-1D93DFF090B7Q36630719-A782E364-EBBD-4E87-8C8D-934CACF16EB0Q36815039-FD1C481D-DEF7-4BF0-94A5-EAA42FFFB750Q37122394-6BE8A550-A683-40B1-BF73-EE1CDE9CC9ACQ37195905-4922026A-D15F-4893-8C83-9860BB3B7A2FQ37364744-93350620-C515-4691-A953-AA679C20B89EQ37378223-9C672260-2ABA-40B4-9E5E-43F51230CF99Q37603906-92154A9D-88F4-40EA-959F-2F18B94AAA68Q37663398-784ECFA1-EE71-4A48-895D-F5CC6C2E884BQ37714981-71602F41-E213-41E5-9F64-A37F812D4917Q37732059-D182D416-90CC-45E4-8ED0-5BE4C8C98DEA
P2860
Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man
description
1994 nî lūn-bûn
@nan
1994 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@ast
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@en
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@nl
type
label
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@ast
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@en
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@nl
prefLabel
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@ast
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@en
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@nl
P2093
P3181
P1476
Bilirubin UDP-glucuronosyltran ...... glucuronidating isoform in man
@en
P2093
B Goldhoorn
J R Chowdhury
N R Chowdhury
P L Jansen
R P Oude Elferink
P304
P3181
P407
P577
1994-07-08T00:00:00Z